Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07125222 | Use of Gocovri to Improve Disability Due to Radiation Encephalopathy | PHASE2 | NOT YET_RECRUITING | 24 | — | — | Sep 1, 2025 | Aug 1, 2028 | Aug 15, 2025 | 1 | United States |
The Disability Rating Scale (DRS) is a tool used to evaluate impairment, disability and handicap caused by brain injury. Scores range from 0 (No disability) to a maximum of 29 (indicating an extreme vegetative state).
| Arm | Type | Description |
|---|---|---|
| Gocovri (extended-release amantidine) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Gocovri (extended-release amantidine) | DRUG | Gocovri is extended release formulation of amantidine. Starting on Day 1, patients will start Gocovri 137mg daily. If there is no dose-limited event after 28 days, the dose will be increased to 274mg daily which will become the new standard dose for the remaining 20 weeks of the patient's participation in the study. |
Inclusion Criteria: * Individuals ≥ 18 years of age. * Individuals with caregivers who are able to complete survey assessments for this study. * Prior brain radiation treatment. * Evidence of moderate-severe confluent white matter hyperintensity on MRI brain scan as judged by neuroradiology impress...